The combination of BRAF inhibitor and MEK inhibitor is one of the first‐line treatments for unresectable BRAF‐mutant melanoma or as an adjuvant therapy. However, some patients who received the combination of dabrafenib and trametinib (CombiDT) or the combination of encorafenib and binimetinib (CombiEB) had adverse events (AEs) including pyrexia. We herein report a patient with BRAF‐mutated melanoma who repeatedly developed elevated levels of D‐dimer and pyrexia after CombiDT and CombiEB treatments. Moreover, concomitant edoxaban prevented these AEs, enabling the patient to continue receiving CombiEB.

No abstract